Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance Journal Article


Authors: Boyiadzis, M. M.; Dhodapkar, M. V.; Brentjens, R. J.; Kochenderfer, J. N.; Neelapu, S. S.; Maus, M. V.; Porter, D. L.; Maloney, D. G.; Grupp, S. A.; Mackall, C. L.; June, C. H.; Bishop, M. R.
Article Title: Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: Clinical perspective and significance
Abstract: Chimeric Antigen Receptor (CAR) T cell therapies - adoptive T cell therapies that have been genetically engineered for a new antigen-specificity - have displayed significant success in treating patients with hematologic malignancies, leading to three recent US Food and Drug Administration approvals. Based on the promise generated from these successes, the field is rapidly evolving to include new disease indications and CAR designs, while simultaneously reviewing and optimizing toxicity and management protocols. As such, this review provides expert perspective on the significance and clinical considerations of CAR T cell therapies in order to provide timely information to clinicians about this revolutionary new therapeutic class. © 2018 The Author(s).
Keywords: leukemia; overall survival; review; cell proliferation; cancer immunotherapy; multiple myeloma; cyclophosphamide; antineoplastic activity; endoplasmic reticulum; t lymphocyte receptor; hematologic malignancy; immune response; antigen specificity; antigen recognition; lymphoma; graft versus host reaction; chimeric antigen receptor; cell therapy; chronic lymphatic leukemia; antigen presenting cell; t lymphocyte activation; interleukin 12; tumor microenvironment; clinical trial (topic); phase 2 clinical trial (topic); phase 1 clinical trial (topic); aplasia; tocilizumab; human; priority journal; crispr cas system; solid malignant neoplasm; tisagenlecleucel t; chimeric antigen receptor immunotherapy; axicabtagene ciloleucel; tisagenlecleucel
Journal Title: Journal for Immunotherapy of Cancer
Volume: 6
ISSN: 2051-1426
Publisher: Biomed Central Ltd  
Date Published: 2018-12-04
Start Page: 137
Language: English
DOI: 10.1186/s40425-018-0460-5
PROVIDER: scopus c7 - 137 c2 - 30514386
PMCID: PMC6278156
PUBMED: 30514386
DOI/URL:
Notes: J. Immunother. Cancer -- Export Date: 2 January 2019 -- Review -- Source: Scopus C7 - 137 C2 - 30514386
Altmetric Score
MSK Authors
  1. Renier J Brentjens
    187 Brentjens